GMP Issues With COVID Vaccines and Drugs are Not New Concerns

By Barbara W Unger

In this report you will see:

  • Why three manufacturing sites for COVID-19 vaccines and drugs received 483 observations
  • An in-depth analysis of these observations based on the author’s expertise
  • Learn how these observations stack up with observations at non-COVID products